Mizuho cuts LeonaBio stock price target on financing concerns
Mizuho reduced its price target for LeonaBio (LONA) to $12 from $13, citing financing concerns after warrants expired unexercised. The stock is down 29% this week. Mizuho maintains an Outperform rating, noting progress in the ELAINE-3 study and a supportive investor base. LeonaBio reported Q3 2026 results, confirming trial enrollment completion by year-end 2026. Other analysts also adjusted price targets.

